Clinical trials: Apixaban
Aortic Stenosis
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis.
- Trial name
- ACASA-TAVI (NCT05035277)
- Testing
- Acetylsalicylic acid, Apixaban, Rivaroxaban
- Where
- 3 sites in Norway
- Volunteers
- 360 people
- Sponsor
- Oslo University Hospital
Atrial Fibrillation (AF), Coronary Arterial Disease (CAD)
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF).
- Trial name
- SMARTDECISION3 (NCT07753200)
- Testing
- Edoxaban, Apixaban
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Atrial Fibrillation
Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the…
- Trial name
- TREND (NCT03474757)
- Testing
- Data Collection
- Where
- Colombia
- Volunteers
- 10,528 people
- Sponsor
- Bayer
Ischemic Heart Disease, Atrial Fibrillation
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.
- Trial name
- INTERMITTENT (NCT04151680)
- Testing
- Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Ischemic Stroke
Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite oral anticoagulation
- Trial name
- HERO (NCT02238470)
- Testing
- oral anticoagulants
- Where
- 30 sites in Italy, Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteer
Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers
The goal of this bioequivalence of two formulations of generic apixaban 5 mg film-coated tablets. Single-dose under fasting conditions and pharmacokinetics will be characterized for a total of 28 healthy adult human subjects.
- Trial name
- NCT06388239
- Testing
- Apixaban 5MG
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- International Bio service
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
Foot Ankle Injuries, Anticoagulants and Bleeding Disorders
A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
Deep vein Thrombosis (Deep Venous Thrombosis, DVT) and Pulmonary Embolism, Pulmonary Embolism, PE) both collectively known as Venous thromboembolism (VTE) (Venous Thrombus Embolism, VTE), is a common clinical disease, and…
- Conditions
- Foot Ankle Injuries, Anticoagulants and Bleeding Disorders, Venous Thromboembolism
- Trial name
- NCT04128254
- Testing
- Apixaban Oral Tablet
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation, Intracerebral Hemorrhage
NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH
To determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) compared with ASA for stroke prevention in patients with a high-risk of atrial…
- Trial name
- NASPAF-ICH (NCT02998905)
- Testing
- NOAC, Acetylsalicylic Acid
- Where
- 9 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Population Health Research Institute
Atrial Fibrillation
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly…
- Trial name
- NCT03026556
- Testing
- Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
- Where
- United States
- Volunteers
- 42,534 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient
Atrial fibrillation (AF) is the most common arrhythmia, and its prevalence is increasing with the aging population [1]. As the prevalence of AF is significantly rising among the population over 70-80 years old and considering the…
- Trial name
- NCT05773222
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 2,002 people
- Sponsor
- Seoul National University Hospital
Hemodialysis Access Failure
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
Taiwan was among the countries with high prevalence of end stage renal disease (ESRD), and more than 90% of ESRD patients in Taiwan received hemodialysis.
- Trial name
- NCT04489849
- Testing
- Apixaban 2.5 MG, Active Control
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital Hsin-Chu Branch
Stroke
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Trial name
- ARCADIA (NCT03192215)
- Testing
- Apixaban, Aspirin
- Where
- 177 sites in United States, Canada
- Volunteers
- 1,015 people
- Sponsor
- Columbia University
Deep Vein Thrombosis
Calf Deep Vein Thrombosis Treatment Trial
The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or…
- Trial name
- NCT03590743
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Pulmonary Embolism, Intermediate-high Risk
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
Pilot randomized study of the sidlenafil efficacy in combination with oral anticoagulants in the treatment of patients with intermediate-high risk of pulmonary embolism
- Conditions
- Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil
- Trial name
- PSCAT (NCT02946944)
- Testing
- Sildenafil/apixaban, apixaban
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Aortic Valve Replacement, Antithrombotic Therapy
Apixaban for the Prevention of Latent Biological Valve Thrombosis
Background: The optimal antithrombotic strategy early after aortic valve replacement surgery with a biological valve remains controversial due to lack of high-quality evidence.
- Conditions
- Aortic Valve Replacement, Antithrombotic Therapy, Bioprosthetic Valve Thrombosis, Rapid Deployment Valves
- Trial name
- NCT06184113
- Testing
- Aortic valve replacement surgery, Computed tomography, Echocardiography
- Where
- Croatia
- Volunteers
- 166 people
- Sponsor
- Clinical Hospital Centre Zagreb
Atrial Fibrillation, Cerebrothromboembolus
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States, and treatment by AF ablation is quickly becoming the favored definitive therapy.
- Conditions
- Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function
- Trial name
- NCT02120560
- Testing
- Atrial Fibrillation Ablation
- Where
- United States
- Sponsor
- University of California, San Francisco
Venous Thromboembolism
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
The purpose of this study is to assess outpatient treatment patterns following hospitalization for venous thromboembolism (VTE). VTE is a condition that occurs when blood clot forms in the vein.
- Trial name
- NCT05795062
- Testing
- apixaban, warfarin
- Where
- United States
- Volunteers
- 13,945 people
- Sponsor
- Pfizer
Venous Thromboembolism, Head and Neck Cancer
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery.
- Trial name
- NCT07189897
- Testing
- Enoxaparin, Apixaban
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Kiranya Arnold